CLINICAL TRIAL SUMMARY

MDACC Study No:2003-1002 (clinicaltrials.gov NCT No: NCT00500422)
Title:Phase I Study of a Combination of Doxil, VELCADE, and Gemcitabine in Advanced Cancer
Principal Investigator:Gerald Falchook
Treatment Agent:Doxil; Gemcitabine; Velcade
Study Status:Terminated
Study Description:The goal of this clinical research study is to find the highest safe dose of
the drug Velcade (bortezomib) that can be given together with gemcitabine and
pegylated liposomal doxorubicin (Doxil) in the treatment of advanced cancer.
The effect of this combination treatment on tumor growth will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Phase I Studies
Phase of Study:Phase I
Treatment Agents:Doxil
Gemcitabine
Velcade
Treatment Location:Independent Multicenter Arrangements
Estimated Length of Stay in Houston:N/A
Supported By:N/A
Return Visit:Patients must return to MDACC about every 3 weeks.
Home Care:The initial or loading doses of all drugs will be given in the clinic.
Subsequent doses may be given by the patient’s local physician.


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Gerald Falchook
Dept:Investigational Cancer Therapeutics
For Clinical Trial Enrollment:713-792-9669
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults